Giuseppe Viale

机构：Istituti di Ricovero e Cura a Carattere Scientifico, European Institute of Oncology · ORCID：0000-0003-1882-7068

发表论文 1278 篇 · 总被引 113571 次 · h-index 157

代表论文

• Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy (2025 · The Lancet · 被引 35)
• Abstract GS1-09: OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer: (2025 · Clinical Cancer Research · 被引 27)
• Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials (2025 · The Lancet Oncology · 被引 7)
• A Global Ring Study: Concordance Between Ventana PATHWAY Anti-HER2/neu (4B5) Companion Diagnostic Assay and Comparators in Detecting HER2-Low Breast Cancer (2025 · Modern Pathology · 被引 5)
• Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin? (2026 · European Journal of Cancer)
• Supplementary Figure S4 from Transcriptomic Insights into Lobular Breast Cancer Biology and Patient Outcomes: Analysis of the MINDACT Clinical Trial (2026)